To our knowledge, no prior studies have focused on PD1/PDL-1 immunotherapy pathway differences between races or the race-specific outcomes for patients that receive immune checkpoint inhibitors for pancreatic cancer. The gene discussed is CD274; the disease is pancreatic neoplasm.